癌症的饮食干预:所有随机对照试验的系统审查
Nosakhare Paul Ilerhunmwuwa1, Abul Hasan Shadali Abdul Khader2, Calvin Smith3
1One Brooklyn Health/Brookdale University Hospital and Medical Center, Brooklyn, NY, USA.
Journal of the National Cancer Institute
|March 2, 2024
概括
这一系统性审查发现,大多数针对癌症患者饮食干预的随机对照试验 (RCT) 是小规模的,重点关注非临床结果. 大规模的RCT没有证明癌症进展或存活率有所改善,这表明饮食作为癌症治疗的证据有限.
科学领域:
- 在瘤学瘤学.
- 营养科学 营养科学
- 临床研究 临床研究
背景情况:
- 之前的审查集中在针对癌症的特定饮食干预措施上.
- 本综述全面评估了所有针对癌症患者饮食干预的随机对照试验 (RCT).
- 检查了广泛的干预措施,患者群体和结果.
研究的目的:
- 系统地审查所有随机对照试验 (RCT),调查癌症患者的饮食干预措施.
- 分析干预措施的多样性,患者群体和测量结果.
- 评估癌症护理中的饮食干预措施的整体证据.
主要方法:
- 进行了2023年1月之前发表的RCT的系统审查.
- 包括测试任何类型癌症患者的饮食干预措施的研究.
- 评估结果如生活质量,功能状态,临床癌症测量,整体存活率和转化标记.
主要成果:
- 确定了252个RCT,涉及31,067名患者;中位数样本大小为71.
- 大多数试验 (73%) 是辅助的,体重/身体组成和转化标记作为常见的初级终点.
- 在结肠,乳腺和前列腺癌的大型RCT中,饮食干预对癌症测量没有影响;只有8项试验满足了与癌症相关的初级终点.
结论:
- 这个领域的大多数RCT都是小规模的,并利用非临床终点.
- 有限的大规模RCT没有显示出对癌症结局的好处.
- 目前的证据表明,对饮食干预措施作为癌症管理中的治疗策略的支持有限.
相关概念视频
Cancer Prevention
6.2K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.2K
Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Hazard Ratio
121
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
121


